Clinical and Economic Burden of Patients With Haemophilia A and B in France: Analysis of a Nationwide Claims Database.

Introduction: There are few data on healthcare resource use and related costs of French haemophilia A (HA) and B (HB) patients.

Aims: This study aimed to describe the profile of HA and HB patients, current disease management, clinical burden and costs.

Methods: Data related to haemophilia patients of all ages alive on 1/1/2022 were extracted from the nationwide French claims database (SNDS).

Real-world oral glucocorticoid use in SLE: a nation-wide population-based study using the French medico-administrative (SNDS) claim database.

Background: Oral glucocorticoids (OCS) remain one of the most important treatments for SLE but are associated with damage. Evidence regarding the real-world use of OCS in nationwide SLE populations is currently lacking. The aim of this study was to analyse OCS use and SLE treatments in French patients with SLE at the national level.

Economic burden of systemic lupus erythematosus and lupus nephritis in France: a nationwide population-based study using the French medico-administrative (SNDS) claims database.

Objectives: Data on the economic consequences of systemic lupus erythematosus (SLE) and lupus nephritis (LN) are scarce in Europe. We aimed to estimate the total direct costs attributable to SLE and LN in France, at the nationwide level.

Methods: Patients with SLE and LN were identified in the French nationwide health insurance database (SNDS).

Basal Insulinotherapy in Patients Living with Diabetes in France: The EF-BI Study.

Introduction: Second-generation basal insulins like glargine 300 U/mL (Gla-300) have a longer duration of action and less daily fluctuation and interday variability than first-generation ones, such as glargine 100 U/mL (Gla-100). The EF-BI study, a nationwide observational, retrospective study, was designed to compare persistence, acute care complications, and healthcare costs associated with the initiation of such basal insulins (BI) in a real-life setting in France.

Methods: This study was conducted using the French healthcare claims database (SNDS).

Respiratory syncytial virus-related hospital stays in adults in France from 2012 to 2021: A national hospital database study.

Background: Respiratory syncytial virus (RSV) causes lower respiratory tract infections (LRTI) that may lead to hospitalization or death. The present study aimed to assess the burden of RSV infections in hospitalized adults.

Methods: RSV-related hospitalizations were identified from the nationwide hospital claims database in France (PMSI) from 2012 to 2021 using ICD-10 codes J12.

Comorbidities in people living with HIV: An epidemiologic and economic analysis using a claims database in France.

Objectives: As people living with HIV (PLHIV) age, the burden of non-HIV related comorbidities increases resulting in additional healthcare costs. The present study aimed to describe the profile, the prevalence and the incremental costs of non-HIV related comorbidities in PLHIV compared to non-HIV matched controls (1:2 ratio) in France.

Methods: The French permanent sample of health beneficiaries (Echantillon généraliste de bénéficiaires [EGB]), a claims database representative of the national population, was used to assess comorbidities in PLHIV which were identified by the ICD-10 diagnosis codes of hospitalization, full healthcare coverage, and drug reimbursements between 2011 and 2014.

The Burden of Severe Asthma in France: A Case-Control Study Using a Medical Claims Database.

Background: Severe asthma (SA) is defined by treatment intensity. The availability of national databases allows accurate estimation of the prevalence, long-term outcomes, and costs of SA.

Objective: To provide accurate information on SA, focusing on comorbidities, mortality, health care resource consumption, and associated costs.

Xafran, a drug utilization study of rivaroxaban in stroke prevention in atrial fibrillation in France using a claim database.

Background: Little is known about the utilization of rivaroxaban in real life treatment settings in France.

Aims: Objectives of this study were to describe the conditions of use and treatment persistence in patients with atrial fibrillation and treated with rivaroxaban for stroke prevention (SP-AF).

Methods: A cohort study was performed using a representative sample of the French nationwide database.

A Delphi-Based Consensus Statement on the Management of Anticoagulated Patients With Botulinum Toxin for Limb Spasticity.

Objective: To create a consensus statement on the considerations for treatment of anticoagulated patients with botulinum toxin A (BoNTA) intramuscular injections for limb spasticity.

Design: We used the Delphi method.

Setting: A multiquestion electronic survey.

Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis.

Objectives: Our objects was to estimate the direct healthcare costs of type 2 diabetes mellitus (T2DM) in France in 2013.

Methods: Data were drawn from a random sample of ≈600,000 patients registered in the French national health insurances database, which covers 90% of the French population. An algorithm was used to select patients with T2DM.

Exposure of children to extremely low frequency magnetic fields in France: Results of the EXPERS study.

The assessment of magnetic field exposure in children is an important point in the context of epidemiological issues. EXPERS is the first study ever carried out measuring personal exposure to extremely low frequency magnetic fields at a national scale, involving 977 French children with 24 h personal measurements. Descriptive statistical analyses were performed for all the children, and only for children where no alarm clock was identified, as in some cases this requirement of the measurement protocol was not respected.

Female rats are protected against oxidative stress during copper deficiency.

Background: Copper deficiency induces a dramatic decrease of superoxide dismutase activity and leads to alteration of antioxidant defense systems.

Methods: and

Objective: Experiments were conducted in weanling male, intact and ovariectomized female rats, fed either a copper-adequate or copper-deficient diet for seven weeks, in order to determine whether endogenous estrogen could modulate oxidative stress and the severity of copper-deficiency.

Results: Feeding male rats a copper-deficient diet induced typical signs of copper deficiency, such as decreased hepatic copper, growth retardation, anemia, heart hypertrophy, pancreas atrophy and hypercholesterolemia.

No antioxidant effect of combined HRT on LDL oxidizability and oxidative stress biomarkers in treated post-menopausal women.

Objective: To compare oxidative stress and LDL oxidizability in postmenopausal women with and without HRT.

Methods: In a cross sectional study, two groups of women, with or without combined per os HRT (1.5-2 mg estrogen associated with 10 mg dydrogesteron), were age and duration of menopause matched.

Beneficial effects of hormonal replacement therapy on chromium status and glucose and lipid metabolism in postmenopausal women.

Objectives: Postmenopausal women exhibit an increased incidence of cardiovascular diseases, and type 2 diabetes mellitus compared with younger women. However, women receiving hormonal replacement therapy (HRT) seem to be protected. Since chromium (Cr) functions in glucose, lipid and corticosteroid metabolism and these variables, as well as Cr status, decline with age, Cr status may be a contributing factor in the effects of hormone replacement therapy.

Trace mineral status in post menopausal women: impact of hormonal replacement therapy.

The risks of disturbances in trace mineral nutrition and metabolism are high following menopause. The aim of the study was to investigate the trace mineral status in postmenopausal women and the influence of hormonal replacement therapy on this status. Forty-four healthy postmenopausal women, aged 50-60 years old participated in the study.